Risk of Serious Immune-Related Adverse Events with Various PD1 and PD-L1 Inhibitors: A Single-Institution, Real-Life, Comparative Study
This study highlights the differences in toxicity profile of various ICIs targeting the PD1/PD-L1 axis in real-life use, as well as the identification of possible predictive biomarkers.
Authors
- J. Deturmeny
- Hervé Pegliasco
- Thomas Escoda (ORCID: https://orcid.org/0000-0002-4060-4365)
- E. Coquet (ORCID: https://orcid.org/0000-0003-4344-0658)
- Guillaume Pénaranda (ORCID: https://orcid.org/0000-0002-7461-4254)
- Manfred Souquet
- Nicolas M. Barrière (ORCID: https://orcid.org/0000-0001-9407-9490)
- L. A. Diaz
- Laurent Chiche (ORCID: https://orcid.org/0000-0002-0582-694X)
- Véronique Brunel (ORCID: https://orcid.org/0000-0002-5783-938X)
- Tiphaine Boucheron
- Chloé Arbault-Bitton
Institutions
- Hôpital Européen (FR)
Publication Details
- Journal
- Therapeutics and Clinical Risk Management
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/tcrm.s479686
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09